sarah_TO said:

The mechanism that matters here is not stomach emptying, it is central.

This answered a question I did not know how to ask. Sending this to two other people who asked me the same thing last week.

From the other side of the consultation, briefly.

kate.chem said:

...but the FDA says semaglutide...

Interesting point. I want to add some regulatory nuance: the FDA labeling reflects the specific clinical trial data submitted for approval. Real-world clinical practice often extends beyond the FDA label based on emerging evidence and clinical judgment.

Example: semaglutide was first approved for diabetes (Ozempic), then obesity (Wegovy). The molecule didn't change — our understanding of its applications expanded. Similarly, semaglutide may evolve as more data accumulates.

james_edin said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

Adding the numbers, since they settle part of this. Practical: unopened, refrigerated at 2 to 8°C; in use, refrigerated and used within the preservative-limited window; never frozen; and a visual check every time — a haze that does not settle is a reason to stop, not to wonder.

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. No action needed from anybody.